Trade Medivir B - MEDIVIR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.08 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.017053% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.005169% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 100 | ||||||||
| Currency | SEK | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Sweden | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.26 |
| Open | 1.24 |
| 1-Year Change | -52.67% |
| Day's Range | 1.22 - 1.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 2, 2025 | 1.26 | -0.02 | -1.56% | 1.28 | 1.30 | 1.24 |
| Apr 1, 2025 | 1.26 | -0.04 | -3.08% | 1.30 | 1.30 | 1.26 |
| Mar 26, 2025 | 1.34 | 0.00 | 0.00% | 1.34 | 1.36 | 1.32 |
| Mar 25, 2025 | 1.34 | 0.02 | 1.52% | 1.32 | 1.34 | 1.32 |
| Mar 24, 2025 | 1.34 | -0.04 | -2.90% | 1.38 | 1.38 | 1.32 |
| Mar 21, 2025 | 1.44 | 0.00 | 0.00% | 1.44 | 1.48 | 1.44 |
| Mar 20, 2025 | 1.44 | -0.04 | -2.70% | 1.48 | 1.50 | 1.44 |
| Mar 19, 2025 | 1.46 | 0.00 | 0.00% | 1.46 | 1.52 | 1.40 |
| Mar 17, 2025 | 1.48 | 0.02 | 1.37% | 1.46 | 1.48 | 1.46 |
| Mar 14, 2025 | 1.42 | 0.06 | 4.41% | 1.36 | 1.42 | 1.36 |
| Mar 13, 2025 | 1.38 | -0.06 | -4.17% | 1.44 | 1.44 | 1.38 |
| Mar 10, 2025 | 1.42 | -0.04 | -2.74% | 1.46 | 1.46 | 1.42 |
| Mar 7, 2025 | 1.54 | -0.02 | -1.28% | 1.56 | 1.60 | 1.48 |
| Mar 6, 2025 | 1.70 | 0.02 | 1.19% | 1.68 | 1.70 | 1.66 |
| Feb 26, 2025 | 1.88 | 0.00 | 0.00% | 1.88 | 1.90 | 1.84 |
| Feb 25, 2025 | 1.88 | -0.08 | -4.08% | 1.96 | 2.08 | 1.84 |
| Feb 24, 2025 | 1.94 | -0.04 | -2.02% | 1.98 | 2.00 | 1.94 |
| Feb 21, 2025 | 1.98 | -0.02 | -1.00% | 2.00 | 2.02 | 1.98 |
| Feb 20, 2025 | 2.00 | 0.04 | 2.04% | 1.96 | 2.02 | 1.96 |
| Feb 19, 2025 | 1.98 | -0.12 | -5.71% | 2.10 | 2.10 | 1.90 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Medivir Company profile
About Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Medivir AB revenues increased 83% to SEK25.5M. Net loss increased 48% to SEK63.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.44 to -SEK1.19.
Equity composition
01/2007, Rigths Issue, 3 new shares for every 5 shares held @ SEK 29 (Factor: 1.224545). 04/2010, Rights Issue, 1 new share for every 4 shares held @ SEK 62 (Factor: 1.10266). 2/2015, complex stock split (Factor: 1.59182) 1/2021, Rights Issue, 1 new share for every 1 share held @ SEK7 (Factor: 1.21788).
| Industry: | Bio Therapeutic Drugs |
Lunastigen 5, 2 tr
HUDDINGE
STOCKHOLM 141 22
SE
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com